Schizophrenia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

  NCT05603104· Dr. Inge Winter· Updated 5 Nov 2026

  “The site in Israel stopped recruitment due to logistic reasons. Other sites are recruiting for 2023-506602-39-00, 2023-506605-19-00, 2023-506617-21-00.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

  NCT05603104· Dr. Inge Winter· Source

• MI-CBTech: A Mobile Intervention for Community Integration in Homeless-Experienced Veterans With SMI

  NCT06138054· VA Office of Research and Development· Source

• Tau Biomarkers in Late-onset Psychosis (LOP)

  NCT06336382· Jeremy Koppel· Source

• Ashwagandha Added to Risperidone for Quality of Life and Inflammation in Schizophrenia

  NCT07917637· Athitah Pratiwi· Source

• Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics

  2024-519836-18-00· Newron Pharmaceuticals S.p.A.· Source

• Target Engagement and Response to Oxytocin

  NCT03245437· University of California, Los Angeles· Source

• A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

  NCT07615426· Janssen Research & Development, LLC· Source

• Real-World Impact of TV-44749 in Adults With Schizophrenia

  NCT07913100· Teva Branded Pharmaceutical Products R&D LLC· Source

• Acute Effects of Partial GABA(A)-Receptor Modulation by GT-002 on Psychophysiological Measures: The TOTEMS Phase II Clinical Trial Targeting Cognitive Impairment Associated with Schizophrenia

  2024-519389-28-00· Region Hovedstadens Psykiatriske· Source

• A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia

  NCT06882785· Bristol-Myers Squibb· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 8
• Organoids 4
• Mendelian Randomization Analysis 69
• CRISPR-Cas Systems 2
• Gene Expression Profiling 44
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 3
• Exome Sequencing 4
• Proteomics 30
• Metabolomics 24
• Mass Spectrometry 7
• Flow Cytometry 1
• Immunohistochemistry 8
• Positron-Emission Tomography 30
• Magnetic Resonance Imaging 380
• Machine Learning 80
• Deep Learning 17
• Cohort Studies 169
• Genome-Wide Association Study 173

• Somatostatin expression is associated with mitochondrial-related gene expression in a brain region-specific manner: Evidence from human transcriptomic analysis.

  Behav Brain Res, Aug 2026

• Transcriptomic characteristics of plasma from Chinese ethnic minority patients with major depressive disorder.

  Transl Psychiatry, Aug 2026

• Analysis of gene co-expression connectivity dynamics implicates aberrant neuron-oligodendroglia interactions in schizophrenia.

  Nat Commun, Jul 2026

• Identification of hub genes involved in early-onset schizophrenia: from genetic susceptibility to predicted regulated gene expression.

  Mol Psychiatry, Jul 2026

• Transcriptomic signatures and neural cell composition in schizophrenia iPSC-derived neuron cultures.

  Cells Dev, Jul 2026

• Blood-based biomarker discovery through integrative transcriptomic and miRNA network analyses in schizophrenia, major depressive disorder, and bipolar disorder.

  Comput Biol Chem, Jun 2026

• Co-expression-based models improve eQTL predictions for transcriptome-wide association studies and highlight new schizophrenia-associated genes.

  Nat Genet, Jun 2026

• Developmentally dynamic, non-convergent transcriptomic profiles in CNV models for schizophrenia risk.

  Mol Psychiatry, Jun 2026

• Integrative Multiomics Analysis Identifies DKK3 as a Germline Susceptibility-Related Regulator of Risperidone Response and Metabolic Risk in Schizophrenia.

  Hum Mutat, Jun 2026

• Machine learning-based integration identifies a 10-gene predictive signature and its classification patterns in schizophrenia.

  Eur Arch Psychiatry Clin Neurosci, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.